Expression pattern of estroprogestinic receptors in sinonasal inverted papilloma
// Agostino Serra 1 , Rosario Caltabiano 2 , Giacomo Spinato 3 , Salvatore Gallina 4 , Salvatore Caruso 5 , Venerando Rapisarda 6 , Paola Di Mauro 1 , Veronica Castro 1 , Angelo Conti 1 , Luisa Licciardello 1 , Luigi Maiolino 1 , Salvatore Lanzafame 2 , Salvatore Cocuzza 1 1 Department of Medical and Surgical Sciences and Advanced Technologies “G. Ingrassia”, ENT Section, University of Catania, Catania, Italy 2 Department of Medical and Surgical Sciences and Advanced Technologies “G. Ingrassia”, Section of Anatomic Pathology, University of Catania, Catania, Italy 3 ENT Department, Rovigo Provincial Hospital, Rovigo, Italy 4 Department of Experimental Biomedicine and Clinical Neurosciences, …
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
Abstract Background Chemotherapy is effective in metastatic pancreatic adenocarcinoma (mPA), but new approaches are still needed to improve patients' survival and quality of life. We have previously published good efficacy and tolerability results on a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI (5FU+irinotecan) regimen. In the present study, we evaluated the same sequence but replaced gemcitabine by the new gemcitabine + nab-paclitaxel standard first-line combination. Patients and methods We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status 0–2 to alternately receive gemcitab…